ERBB2 and breast carcinoma: Many studies have demonstrated overexpression and amplification of the HER2 transmembrane tyrosine kinase receptor in approximately 20–30% of breast cancer cases, and this is associated with not only poor clinical outcome, but also response to clinical therapies [6–8].